Related references
Note: Only part of the references are listed.Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan
Isao Kamae et al.
CLINICAL THERAPEUTICS (2015)
50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study
Renate B. Schnabel et al.
LANCET (2015)
Graphical Representation of Life Paths to Better Convey Results of Decision Models to Patients
Stefania Rubrichi et al.
MEDICAL DECISION MAKING (2015)
COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NOACS AND WARFARIN, DURING HOSPITALIZATION IN THE PRIVATE BRAZILIAN HEALTH SYSTEM
S. Tanaka et al.
VALUE IN HEALTH (2015)
COST-EFFECTIVENESS OF APIXABAN VERSUS OTHER NEW ORAL ANTICOAGULANTS AND WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION IN VENEZUELA
Y. Fernandez Avila et al.
VALUE IN HEALTH (2015)
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society
Craig T. January et al.
CIRCULATION (2014)
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
Paul Dorian et al.
EUROPEAN HEART JOURNAL (2014)
Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
Martin Krejczy et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2014)
Epidemiology and disease burden of ischemic stroke in Taiwan
Chung-Yu Chen et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2013)
Rivaroxaban versus Warfarin in Japanese Patients with Nonvalvular Atrial Fibrillation for the Secondary Prevention of Stroke: A Subgroup Analysis of J-ROCKET AF
Norio Tanahashi et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2013)
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Amanda R. Harrington et al.
STROKE (2013)
Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Doug Coyle et al.
VALUE IN HEALTH (2013)
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation
Hooman Kamel et al.
NEUROLOGY (2012)
Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database
Sally Lee et al.
BMJ OPEN (2012)
2011 ACCF/AHA/HRS Focused Updates Incorporated into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation
Valentin Fuster et al.
CIRCULATION (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese
Kuo-Liong Chien et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Newly Identified Events in the RE-LY Trial
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Compliance with Antithrombotic Prescribing Guidelines for Patients with Atrial Fibrillation-A Nationwide Descriptive Study in Taiwan
Li-Jen Lin et al.
CLINICAL THERAPEUTICS (2008)
Status of the epidemiology of atrial fibrillation
William B. Kannel et al.
MEDICAL CLINICS OF NORTH AMERICA (2008)
Characteristics of hospitalized patients with atrial fibrillation in Taiwan: A nationwide observation
Cheng-Han Lee et al.
AMERICAN JOURNAL OF MEDICINE (2007)
Mortality risk attributable to atrial fibrillation in middle-aged and elderly people in the Japanese general population - Nineteen-year follow-up in NIPPON DATA80
Masaki Ohsawa et al.
CIRCULATION JOURNAL (2007)
Aspirin for the primary prevention of cardiovascular disease in women - A cost-utility analysis
Michael Pignone et al.
ARCHIVES OF INTERNAL MEDICINE (2007)
Preference-based EQ-5D index scores for chronic conditions in the United States
Patrick W. Sullivan et al.
MEDICAL DECISION MAKING (2006)
A national catalog of preference-based scores for chronic conditions in the United States
PW Sullivan et al.
MEDICAL CARE (2005)
A meta-analysis of quality-of-life estimates for stroke
TO Tengs et al.
PHARMACOECONOMICS (2003)
Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study
AS Go et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
